Breast cancer is the most common cancer among women worldwide and causes significant morbidity and mortality (1). According to the 2009 statistics of the Turkish Statistical Institute (TUIK), the leading cancer and the seventh-most-frequent cancer among women were breast and ovarian carcinoma, respectively. Among Turkish women, the incidence of breast cancer and ovarian carcinoma is 23% and 3.9%, respectively. Therefore, breast and ovarian carcinoma are important health problems for Turkish society. Furthermore, consanguineous marriages, especially among first cousins, are quite common in Turkey. This may lead to higher cancer risks, especially in families with cancer histories. It is very important to detect hereditary cancer risk using genetic testing for individuals in high-risk families as well as genetic testing, if applied correctly. Hence it is very important to determine the limits and content of genetic tests.
Frequency of Rearrangements Versus Small Indels Mutations in BRCA1 and BRCA2 Genes in Turkish Patients with High Risk Breast and Ovarian Cancer
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Several syndromes are known to be involved in the development of breast and ovarian tumors such as hereditary breast and ovarian cancer syndrome, Li-Fraumeni syndrome, Cowden disease, hereditary non polyposis colon carcinoma (HNPCC), and Peutz-Jeghers syndrome (6) . Nowadays, all cancer predisposing syndromes can be tested genetically, requested by either physicians or licensed genetic counselors. Clinical identification of these syndromes is beneficial in reducing the risk of cancer in mutation-carrying individuals. Affected persons can take preventative precautions such as screening, chemoprevention, or prophylactic surgery for the organ or tissue. Detected at early stages, prophylactic measures can be used for definitive cancer prevention (5) . Genetic testing, genetic counseling, and the quality and ability of laboratories to test genes are significant factors.
In our study, we evaluated the rate of rearrangements of the genes BRCA1 and BRCA2 in 1809 patients at high risk for breast and ovarian carcinoma, as the current rearrangement rate is not known in the Turkish population. Rearrangements are not investigated in many Turkish laboratories in routine BRCA testing. We conducted the study to emphasize the importance of examining rearrangements while conducting BRCA1 and BRCA2 tests, and to determine the content and limits of the tests.
Material and Methods
General features of patient group: The Oncology Institute Breast and Ovarian Cancer patient cohort compromises high-risk patients having strong family history of cancer, early age of cancer diagnosis, triple negativity, bilateral breast cancer, multifocal localizations of tumor, mixed types of histology results, case of male breast cancer in family from every geographic region of Turkey between 1994 and 2016. 1809 cases were referred to our center from all geographic regions. The diagnoses of 1809 patients were confirmed with their histopathology reports before a genetic counseling session. Patients who agreed to BRCA1 and BRCA2 genetic testing were asked to complete a questionnaire regarding their family histories. High-risk patients were selected in accordance with the National Comprehensive Cancer Network (NCCN) criteria for breast/ovarian cancer. Informed consent was obtained from all participants in the study. The control group was included 125 healthy adults who have no family history on cancer and matched age, gender and ethnicity according to patients group. The study was approved by the Ethics Committee of Istanbul Medical Faculty at Istanbul University (2011/1425-681). The number of patients and patients' diagnoses in the study subgroups are given in Table 1 
Multiplex ligation-dependent probe amplification (mlpa) and copy number variation (cnv) analysis:
We evaluated rearrangements using both the MiSeq NGS platform and MLPA analysis. To calculate CNVs, 300X coverage was used. MLPA analysis was also used to confirm the CNV results from the MiSeq Illumina. MLPA analysis was performed using MRC-Holland probe sets for BRCA1 (P087/P002) and BRCA2 (P045/ P077) genes. The manufacturer's instructions were followed. At least one negative and three normal controls were run in each experimental batch, including DNA molecular weight markers. Amplified DNA was run on a Beckman Coulter DNA sequencer (Beckman Coulter, CEQ8000 and GXL, USA) for fragment analysis. Row data of fragment analyses were analyzed using Coffalyser analysis software and peak areas were calculated using a Coffalyser algorithm. All experiments per patient were performed using four probe sets for both BRCA1 and BRCA2 genes to avoid false-negative and positive results, and to confirm deletions and duplications.
Positive results for pathogenic mutations were repeated with two independent experiments using two probe sets for each gene. Confirmation analysis of rearrangement results from NGS data was replicated by using MLPA analysis with two probe sets for each gene. Confirmation analysis of rearrangement results from MLPA analysis was repeated using MLPA analysis in two independent experiments using both normal and confirmation probe sets for each gene. All positive results were confirmed at least five times in our data set.
All genetic tests were run in the laboratory of Cancer Genetics Department in Oncology Institute. The laboratory is a reference center for BRCA testing in Turkey for both genotyping and genetic counseling.
Statistical analysis
Statistical analysis was performed with Statistical Packages for the Sıcial Sciences (SPSS) version 20 (IBM Corp.; Armonk, NY, USA). Demographic and clinical features of 1809 patients in our cohort were compared with BRCA mutation status using Chi-square tests. The rearrangements prevalence was calculated for the cohort defined by age and family history.
Results
We searched for patients at high-risk of breast and ovarian cancer across seven different regions of Turkey in order to evaluate the prevalence and spectrum of rearrangements of BRCA1 and BRCA2 genes. We also aimed to emphasize the importance of examining rearrangements while conducting BRCA1 and BRCA2 tests, and to determine the content and limits of the tests.
Families were selected according to the NCCN criteria for breast/ovarian cancer. In the cohort, the patients with breast and ovarian cancer have family histories with breast, ovarian and other types of cancer at first and second-degree relatives mostly. All patients were investigated for both small indels and rearrangements of BRCA genes using DNA sequencing and MLPA analysis. Both CNVs and MLPA assays were used to detect the rearrangements of BRCA1 and BRCA2 genes. The study included 1809 patients, who were identified and confirmed through the cancer genetics clinic in our institution by a genetic counselor and a physician according to NCCN criteria.
The number of patients and the distribution of patients according to their diagnoses are given in Table 1 . The mean age at diagnosis was 41.9±9.9 years for BRCA non-carriers and 40.6±9.7 years for carriers with BRCA1 rearrangements in the cohort. Rearrangements in BRCA1 were observed in 25 of 1809 (1.4%) patients with breast and ovarian cancer who had a high-risk family history. All rearrangements in our study population were found in the BRCA1 gene. No BRCA2 rearrangements were found among the 1809 patients. However, four BRCA mutations (3.2%) were found in the healthy controls.
The overall frequency of mutations (small indels and rearrangements) in BRCA1 and BRCA2 genes of patients at high-risk for breast and ovarian cancer was 17% in the cohort. In patients with a high risk of breast cancer, the total frequency of all mutations and rearrangements in BRCA1/2 genes was 15.5% (222/1473) and 1.70% (18/1086), respectively. The highest frequency of rearrangements among patients with breast cancer was 7.7% (2/26) in patients who had ovarian carcinoma as a secondary tumor. The frequency of rearrangements was also high in patients with triple-negative breast cancer (3.7%, 8/215). Rearrangements were found in 5.9% (5/85) of patients with bilateral breast cancer. No rearrangements were detected in Turkish patients with male breast cancer although the overall BRCA1 and BRCA2 gene mutation rate was 15.4% (6/39) in that subgroup (Table 1) . A total of 293 mutations were identified in the 1809 patients with breast/ovarian cancer ( Table 2 ). Of these, 189 patients had frameshift mutations with a frequency of 63.5%. The frequency of nonsense mutations was 16%. The percentages of missense and splice error mutations were 5.8% and 6.2%, respectively ( Table 2 ).
The overall mutation frequency of patients with ovarian cancer was 24% (90/370) for both small indels and rearrangements. The frequency of rearrangements in Turkish patients with ovarian cancer was found as 4% (9/206). The rearrangements percentage was 4% (7/170) in patients who had ovarian tumors only. The subgroups of patients with ovarian cancer and other types secondary tumors revealed no rearrangements.
A total of 25 rearrangements in BRCA1 were identified among the 1809 patients. We found that 2% (25/1262) of Turkish patients with a family history of breast and ovarian cancer had rearrangements in the BRCA1 gene. Sixteen rearrangements were observed in patients with breast cancer with a frequency of 64% (16/25). Nine of the detected 95
BRCA1 gene rearrangements were in ovarian cancer (36%, 9/25) and eight were in triple-negative breast cancer (62%, 8/13) ( Table 3) .
Twenty-five BRCA1 gene rearrangements were detected in our cohort (details are given in Table 4 ). Overall, 84% (21/25) of deletions and 16% (4/25) of duplications were detected among the rearrangements (Table 4 ). The most common alteration (10/25) was exon 18-19 deletion (Table 4 ) (Figure 1 ). The frequency of exon 18-19 deletion was 40% (10/25) in patients with a family history of breast and ovarian cancer, and all patients with mutations lived in the Black Sea region of Turkey. The second most common rearrangement was exon 1-21 deletion, which was seen with a frequency of 12% (3/25) in our cohort. The remaining thirteen different mutations were detected with frequencies of 4-8%.
The average age at diagnosis, histopathology, and family histories of patients among carriers of BRCA1 gene rearrangements are given in Table  5 . The mean age at diagnosis was 40.6±9.7 years for BRCA1 rearrangement carriers. Of 18 patients, 16 patients with breast cancer had invasive ductal carcinoma (IDC), one had invasive lobular carcinoma (ILC) and one had ductal in situ carcinoma (DCIS). With the exception of one patient, all patients with ovarian cancer had serous histopathology.
Deletions of both exons 1-21 and 18-19 were found frequently in our study group. All patients who carried BRCA1 gene exon 1-21 deletions had a strong history of breast cancer. In addition to four cases of breast Table 4 . Types of rearrangements and their percentages found in our study group cancer in all of these families, there was at least one case of ovarian cancer, and also other types of cancer in all patients with mutated exon 1-21 deletions who lived in the Marmara region. When we examined the family history of patients with exon 18-19 deletions, there was at least one case of other cancers in the majority of families. In addition, cases of breast cancer and many ovarian cancers were observed. It was determined that all patients who carried exon 18-19 deletions were born and lived in the Black Sea region (Figure 2 ). There were only four large duplications found in patients with breast cancer and ovarian cancer.
Distribution of the different types of rearrangements in the Cohort
Types of rearrangements Numbers of rearrangements (%)
The distribution of patients with carriers of rearrangement according to geographic regions of Turkey were 59.1% in the Black Sea region, 27.3% in the Marmara region, 4.5% in the Eastern Anatolia region, and 9.1% in the Central Anatolia region (Figure 2 ). Even though there were small indel mutations in the remaining three regions, no rearrangements were found.
Discussion and Conclusions
Three previous studies have detected rearrangements in the Turkish population. The first study was based on with 667 unselected patients with ovarian cancer and 27 rearrangements were found with a frequency of 4%. Most (25/27) rearrangements were found in patients with hereditary ovarian cancer (7). The rearrangement ratio (40.9%) given by Aktaş et al. (7) for patients with ovarian cancer who had family histories was very high according to the international literature (4, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . The second study investigated the rearrangement ratio in patients with hereditary breast cancer, but with a small sample size. In the study, only 16 patients with hereditary breast cancer were investigated for rearrangements and none was observed. Manguoğlu et al. (18) 1.9% and their findings gave no information about the rest of the country and hereditary ovarian cancer. All authors suggested that comprehensive studies should be performed in the Turkish population.
Hence there are no clear results about rearrangement ratios in the Turkish population. Consequently, the rearrangement of BRCA1 and BRCA2 genes are not routinely investigated in most clinical genetics laboratories in Turkey. This leads to conflicts between clinics and institutional laboratories, and it also affects the correct management of patients. BRCA1 and BRCA2 mutation screening is becoming more important in clinical practice for treatment options such as PARP inhibitors. The effective management of patients at high risk for breast and ovarian cancer depends on the identification of all mutations such as small indels and rearrangements, which can be screened using different molecular techniques or deep coverage. The knowledge of mutations could be used for risk reduction and chemoprevention as well as treatment options in patients and their relatives. Therefore, this study's goal was to identify the percentage of rearrangements in Turkish patients at high risk for breast and ovarian cancer within a large cohort and to ensure compatibility between laboratories in Turkey.
Many studies have revealed rearrangement frequencies with wide variations for different populations around the world. Judkins et al. (4) found that the rearrangement percentage was 6-10% for all mutations in BRCA1 and BRCA2 genes. Palma et al. (11)reported rearrangements a frequency of 18% in a specific population. Arnold et al. (20) found that rearrangements accounted for 12.7% in an admixture American population. Kwong et al. (17) showed that the rearrangement rate was 8.7% in the Chinese population. French and Czech population frequencies were 6-7.7%, and a high frequency of BRCA2 gene rearrangements was determined in the French population (15) . Rearrangement frequencies were between 3-3.7% in Australian and Korean populations (9, 13) . Gutierrez-Enriquez et al. (10) detected 1.5% rearrangements in the Spanish population. The rearrangement rate was 0-1% in Chilean, Sri Lankan, and Finnish populations (12, 14, 16) . However, there are still no clear data for many specific populations and laboratories that perform BRCA testing using only DNA sequencing or both DNA sequencing and rearrangement testing, which poses problems in terms of the selective use of treatments such as risk reduction surgery, preventive medicine, chemoprevention, and specific drugs such as PARP inhibitors.
In our study, the rearrangement of BRCA1 and BRCA2 genes were investigated using CNV analysis with next-generation sequencing and MLPA analysis in 1809 Turkish patients at high risk for breast and ovarian cancer. Among the 1809 patients, we detected only 25 BRCA1 gene rearrangements with a frequency of 2% (25/1262) versus 15% (268/1785) small indel mutations. Our findings indicate that it would be beneficial to test patients with high-risk family histories to better estimate the probability of mutations.
We found that all rearrangements were located on the BRCA1 gene in our cohort. Our results confirmed the higher prevalence of rearrangements in the BRCA1 gene versus the BRCA2 gene documented in previous reports (21) (22) (23) (24) (25) .
In our study group, the rearrangement rate was high in patients with ovarian cancer (4%, 9/206), triple-negative breast cancer (3.7%, 8/215), bilateral breast cancer (5.9%, 5/85), and patients with breast and ovarian cancer (7.7%, 2/26). Therefore, in high-risk patients, rearrangement testing should be included in standard BRCA1 and BRCA2 gene tests. Furthermore, it was determined that the frequency of rearrangements differed across various geographic regions in Turkey.
In our study, exon 18-19 deletion was the most common rearrangement and all mutation carriers were born and lived in the Black Sea region. Aktaş et al. (7) and Aydın et al. (19) reported the same mutation with a low percentage in a small group of patients from the same region Therefore, we think that exon 18-19 deletion could be a regional alteration specific to the Black Sea region. However, exon 18-19 deletions (40%, 10/25) were the most frequent rearrangements in our cohort. Exon 1-2 deletions (27.8%) were the most common rearrangements in the study by Aktaş et al. (7) in a Turkish population. However, their study group was very small, with 61 patients at high risk for ovarian cancer. In our study, half of the exon 18-19 deletion carriers were diagnosed as having breast cancer, the other half had ovarian cancer. When we examined the family history of patients with exon 18-19 deletions, there was at least one case of other cancers in the majority of families. In addition, there were breast and ovarian cancers.
The second most common mutation was the exon 1-21 deletion (12%, 3/25), which was found in patients living in the Marmara region. All exon 1-21 deletion carriers had breast cancer, and at least 4 cases of breast cancer and one case of ovarian cancer, and other types of cancer were seen in their families.
The cohort included 39 male patients with breast cancer. No rearrangements were found in this subgroup, although the percentage of small indel mutations was 15.4% (6/39). The studies performed by Manguoğlu et al. (18) and Falchetti et al. (26) also showed that there were no rearrangements in breast cancer in Turkish and Italian men, respectively. Another study in a Brazilian population showed that the rearrangement rates in men with breast cancer were less than 1% (27) .
In conclusion, rearrangements found in the BRCA1 gene were present in a considerable proportion of the mutations detected among women who were being treated at a cancer genetics clinic for breast and ovarian cancer risk assessment. Some rearrangements are more common in specific regions of Turkey. Patients at high risk for ovarian cancer, triple-negative breast cancer, and bilateral breast cancer, and patients with breast and ovarian cancer should be tested for rearrangements. Furthermore, the analysis of rearrangements should be part of BRCA1 and BRCA2 testing and a standard application for Turkish patients at high risk for breast and ovarian cancer.
According to our results, there is no longer any doubt as to whether rearrangements should be tested in patients at high risk for breast and ovarian cancer in Turkey. Rearrangement testing should include BRCA1 and BRCA2 analyses in all routine genetic tests in Turkey. We think that our results have clarified the limits and contents of BRCA1 and BRCA2 testing in Turkey.
